Pharmaceutical intermediates
Sotorasib Intermediates
11 pharmaceutical intermediates for Sotorasib. Indication: Colorectal Cancer; Non-Small Cell Lung Cancer.
About Sotorasib
- Originator
- Amgen Inc
- Indication
- Colorectal Cancer; Non-Small Cell Lung Cancer
- Approved Date
- 01/20/2023
- NCE Patent
- 05/28/2026
- DS/DP
- 05/21/2038
Available intermediates
11 intermediates currently listed for Sotorasib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | 2252403-82-8 | / | / |
| tert-butyl (S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate | 2252403-84-0 | / | / |
| 4-[(S)-4-Boc-2-methyl-1-piperazinyl]-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methyl-3-pyridyl)pyrido[2,3-d]pyrimidin-2(1H)-one | 2252403-85-1 | / | / |
| Potassium Trifluoro(2-fluoro-6-hydroxyphenyl)borate | 2252415-10-2 | / | / |
| 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | 2300966-23-6 | / | / |
| 2,6-Dichloro-5-fluoronicotinamide | 113237-20-0 | / | / |
| isopropyl-4-methylpyridin-3-amine | 1698293-93-4 | / | / |
| Fluoro-6-hydroxyphenylboronic acid | 1256345-60-4 | / | / |
| (S)-4-N-Boc-2-methylpiperazine | 147081-29-6 | / | / |
| 2-Fluoro-6-methoxyphenylboronic acid | 78495-63-3 | / | / |
| 2-Fluoro-6-hydroxybenzeneboronic acid pinacol ester | 1534369-41-9 | / | / |
Building toward Sotorasib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →